Bioceres Crop : 3Q23 Earnings Presentation

BIOCERES CROP SOLUTIONS

F I S C A L

Third Quarter

2 0 2 3

THIRD QUARTER 2023

BIOCERES CROP SOLUTIONS

Disclaimer

This Presentation is for informational purposes only and does not constitute an offer or invitation to sell, a solicitation of an offer to buy, or a recommendation to purchase any equity, assets, business, debt or other financial instruments of the Company or any of its affiliates, and shall not form the basis of any contract, nor shall it be construed in any manner as a commitment on the part of any person to proceed with any transaction. Any reproduction of this Presentation, in whole or in part, or the disclosure of its contents, without the prior consent of the Company is prohibited. By accepting this Presentation, each recipient agrees to use this Presentation for the sole purpose of evaluating.

Forward-Looking Statements

This communication includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include estimated financial information and , among others, statements related to the expected or potential impact of the novel coronavirus (COVID-19) pandemic, and the related responses of the government, clients and the Company, on our business, financial condition, liquidity position and results of operations, and any such forward-looking statements, whether concerning the COVID-19 pandemic or otherwise, involve risks, assumptions and uncertainties. Such forward-looking statements are based on management's reasonable current assumptions, expectations, plans and forecasts regarding the Company's current or future results and future business and economic conditions more generally. Such forward-looking statements involve risks, uncertainties and other factors, which may cause the actual results, levels of activity, performance or achievement of the Company to be materially different from any future results expressed or implied by such forward- looking statements, and there can be no assurance that actual results will not differ materially from management's expectations or could affect the Company's ability to achieve its strategic goals, include the uncertainties relating to the impact of COVID-19 on the Company's business, operations and financial results and the other factors that are described in the sections entitled "Risk Factors" in the Company's Securities and Exchange Commission filings updated from time to time. Therefore, you should not rely on any of these forward-looking statements. All forward- looking statements contained in this release are qualified in their entirety by this cautionary statement. Forward- looking statements speak only as of the date they are or were made, and the Company does not intend to update or otherwise revise the forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, except as required by law.

2023	Industry and Market Data
Unless otherwise noted, the forecasted industry and market data contained in the assumptions for the projections are
	based upon the Company's management estimates and industry and market publications and surveys. The
QUARTER	information from industry and market publications has been obtained from sources believed to be reliable, but there
can be no assurance as to the accuracy or completeness of the included information. The Company has not
	independently verified any of the data from third-party sources, nor has the Company ascertained the underlying
	economic assumptions relied upon therein. While such information is believed to be reliable for the purposes used
	herein, none of the Company, its affiliates, their respective directors, officers, employees, members, partners,
THIRD	shareholders or agents makes any representation or warranty with respect to the accuracy of such information. These
materials are highly sensitive and confidential and being supplied to you solely for your information and for use in this
	Presentation.

Financial Information Presentation

Historical financial information of Bioceres has been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board ("IFRS"). Investors should note that IFRS differs from generally accepted accounting principles in the United States ("US GAAP"), and investors should consult their own professional advisors for an understanding of the difference between IFRS and US GAAP and how those differences might affect such financial statements.

Use of Non-IFRS Financial Measures

This Presentation includes certain non-IFRS financial measures. These non-IFRS measures are an addition, and not a substitute for or superior to measures of financial performance prepared in accordance with IFRS and neither should be considered as an alternative to net income, operating income or any other performance measures derived in accordance with IFRS or as an alternative to cash flows from operating activities as a measure of our liquidity.

The Company believes that these non-IFRS measures of financial results provide useful supplemental information to investors about the Company and its results. The Company's management uses these non-IFRS measures to evaluate the Company's financial and operating performance and make day-to-day financial and operating decisions. The Company also believes that these non-IFRS measures are helpful to investors because they provide additional information about trends in the Company's core operating performance prior to considering the impact of capital structure, depreciation, amortization and taxation on its results. However, there are a number of limitations related to the use of these non-IFRS measures and their nearest IFRS equivalents. For example, other companies may calculate non-IFRS measures differently, or may use other measures to calculate their financial performance, and therefore the Company's non-IFRS measures may not be directly comparable to similarly titled measures of other companies.

In this presentation, we discuss non-IFRS measures as forward-lookingnon-IFRS measures.

Copyrights and Trademarks

All materials contained in this Presentation are protected by copyright laws and may not be reproduced, republished, distributed, transmitted, displayed, broadcast or otherwise exploited in any manner. This Presentation contains trademarks, service marks, and trade names belonging to the Company, its affiliates and other entities and cannot be used without express written consent. Trademarks, service marks, copyrights and trade names referred to in this Presentation, including logos, may appear without the ®, © or TM symbols, but the lack of such symbols is not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend the use or display of other entities' trademarks, service marks, copyrighted material or trade names to imply a relationship or affiliation with, or endorsement or sponsorship of, the Company by any other entities or persons.

00

01

02

03

BIOCERES CROP SOLUTIONS

Key Business

&

Financial Highlights

THIRD QUARTER 2023

3Q23 revenues up 33%, with top-line growth primarily driven by initial proceeds from strategic partnership with Syngenta. LTM adjusted EBITDA at $85.3 million

Brazil's National Biosafety Commission provided HB4 Wheat full approval for commercialization and cultivation, unlocking a new

market opportunity for HB4 technology

HB4 Soy advancing favorably in Brazil with initial varieties outperforming top commercial materials with groundbreaking farmers

Published Each Step We Take, 2022 Sustainability Report, documenting our journey in developing and bringing to market technologies to make agriculture more resilient and sustainable

01

02

03

04

BIOCERES CROP SOLUTIONS

YTD Revenue Evolution

THIRD QUARTER 2023

Outstanding revenue performance with	Historical drought in Argentina,	Recognition of initial proceeds from	+28%
robust growth across all segments.	partially offset by growth in	strategic partnership with Syngenta
Advanced sales in anticipation of the	North America and first-time	fully offset the negative impact of	315.1
HB4 Soy sales	extended drought in Argentina
challenging weather in Argentina
		246.2	02
			03

+71%			04
	-7%	33%
			05
	127.1
	101.1	94.4	93.6

74.5	70.6

1Q22	1Q23	2Q22	2Q23	3Q22	3Q23	YTD 2022	YTD 2023
Pro forma1		Pro forma1		Pro forma1		Pro forma1

Notes:

1. Numbers presented for FY22 are pro forma comparable financials including Pro Farm

3Q23

3Q22 Pro forma1

3Q23

Revenue by Segment

Recognition of revenues from Syngenta agreement to compensate for transition costs as countries are onboarded in CY23

Negative impact of the extended drought in Argentina on product sales, particularly in micro-beaded fertilizers

($ Million)

21.3

70.6 45.9

3.5

Reporting Segment	Crop Nutrition
Key Drivers by Segment	Inoculants - Syngenta
	agreement
	Micro-beaded
	fertilizers in Argentina

43.5

+104%

Seed & Integrated Products

Seed treatment packs

93.6 44.4 03

-3%

04

05

06

5.7

+65%

Crop Protection

Insecticides, fungicides and adjuvants in Argentina

Notes:

1. Numbers presented for FY22 are pro forma comparable financials including Pro Farm